Weekly Semaglutide Improves Quality of Life for Patients With Diabetes and Kidney Disease

Researchers presenting at the 63rd European Renal Association Congress in Glasgow reported that semaglutide administered once weekly improved health-related quality of life in adults with diabetes and chronic kidney disease, according to data from the FLOW trial.

The trial, described as a landmark study, examined outcomes in patients receiving the weekly injection. Researchers measured changes in quality of life metrics among the participant group.

Scientists collected data on how the medication affected patients' physical functioning, symptom burden, and overall well-being. The trial included adults with diabetes who also had kidney disease diagnoses.

Results showed measurable improvements across health-related quality of life assessments in participants who received semaglutide compared to other treatment approaches studied. Researchers noted improvements in multiple domains tracked during the trial period.

The FLOW trial represents one of several recent studies examining semaglutide's effects beyond weight management. Earlier research has explored the drug's impact on cardiovascular and kidney outcomes in various patient populations.

Semaglutide belongs to a class of drugs called GLP-1 receptor agonists, originally developed for diabetes management. Regulatory agencies have approved the medication for both diabetes and weight loss treatment in recent years.

Presentation of the FLOW trial results at the ERA Congress adds to a growing body of clinical evidence regarding the drug's broader health effects. The congress convenes nephrologists and kidney disease specialists from across Europe annually.

The trial data comes as healthcare systems continue evaluating how GLP-1 receptor agonists fit within treatment protocols for patients managing multiple chronic conditions. Clinicians have expressed interest in understanding quality of life improvements alongside traditional clinical markers.